IDH1 and acute myeloid leukemia: In the pivotal Phase II study (NCT02719574) of 153 IDH1 inhibitor-naïve R/R AML patients with an IDH1 R132 mutation, the rate of CR was 32% and the median duration of CR was 28.1 months26.